Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Inflectra is a prescription tumor necrosis factor blocker containing infliximab-dyyb. It is biosimilar to Remicade. Current labeling includes Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis under indication-specific criteria.
read more about inflectra ...Infliximab-dyyb binds to soluble and transmembrane forms of tumor necrosis factor alpha and inhibits binding to TNF receptors. This reduces inflammatory signaling associated with several immune-mediated diseases.
Inflectra is used in adults with Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or plaque psoriasis. Pediatric labeling includes moderately to severely active Crohn disease and ulcerative colitis in patients age 6 and older.
Adult and pediatric Crohn disease and ulcerative colitis use 5 mg per kg intravenously at weeks 0, 2, and 6, then every 8 weeks. Rheumatoid arthritis uses 3 mg per kg on the same induction schedule and then every 8 weeks with methotrexate. Ankylosing spondylitis uses 5 mg per kg at weeks 0, 2, and 6, then every 6 weeks.
Inflectra carries boxed warnings for serious infections and malignancies. Risks include tuberculosis, invasive fungal infections, bacterial sepsis, lymphoma, and other cancers. Other serious concerns include hepatitis B reactivation, liver toxicity, heart failure, blood-cell abnormalities, neurologic reactions, and serious infusion reactions.
Yes. Inflectra contains infliximab-dyyb and is biosimilar to Remicade.
Current labeling includes Crohn disease and ulcerative colitis in patients age 6 and older.
The labeled regimen uses 5 mg per kg intravenously at weeks 0, 2, and 6.
Yes. The boxed warnings concern serious infections and malignancies.
Biosimilar Product Information - U.S. Food and Drug Administration. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Date Accessed October 2, 2026.
DailyMed - INFLECTRA - infliximab-dyyb injection, powder, lyophilized, for solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f. Date Accessed October 2, 2026.
FDA Approves Inflectra, a Biosimilar to Remicade. https://www.fda.gov/news-events/press-announcements/fda-approves-inflectra-biosimilar-remicade. Date Accessed October 2, 2026.
Infliximab Injection - MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a604023.html. Date Accessed October 2, 2026.
Purple Book Search - Inflectra. https://purplebooksearch.fda.gov/index.cfm?blaNo=125544&event=productdetails. Date Accessed October 2, 2026.